Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 15;10(22):5318.
doi: 10.3390/jcm10225318.

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?

Javier P Gisbert  1 , María Chaparro  1
Affiliations
Review

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?

Javier P Gisbert et al. J Clin Med. .

Abstract

Background: About a third of patients with inflammatory bowel disease do not respond to anti-tumour necrosis factor (anti-TNF) therapy, which is challenging.

Aim: To review the current data on the two main strategies when facing primary non-response to an anti-TNF agent in inflammatory bowel disease: changing to a second anti-TNF (switching) or to a drug with another mechanisms of action (swapping).

Methods: We performed a bibliographic search to identify studies reporting on efficacy of any biologic treatment after primary anti-TNF non-response.

Results: The efficacy of a second anti-TNF is lower when the reason to withdraw the first one is primary failure. Nevertheless, switching to another anti-TNF even after primary failure may still be effective in some patients. Both vedolizumab and ustekinumab have generally been shown to be less effective in anti-TNF exposed patients. However, despite primary anti-TNF failure, patients may respond to vedolizumab or ustekinumab in a limited but considerable number of cases. The cause for swapping (primary vs. secondary anti-TNF failure) seems to have limited effect on vedolizumab efficacy. Primary anti-TNF non-response seems to be a clearer predictor of treatment failure for ustekinumab. Unfortunately, the two main strategies to treat specifically a patient with primary non-response to an anti-TNF agent-switching to a second anti-TNF or swapping for vedolizumab/ustekinumab-have not been properly compared.

Conclusion: The data reviewed in the present study clearly emphasise the imperative need to carry out head-to-head randomised trials in patients exposed to anti-TNF agents in general, and specifically in those with primary non-response to these agents.

Keywords: anti-TNF; inflammatory bowel disease; primary failure; ustekinumab; vedolizumab.

PubMed Disclaimer

Conflict of interest statement

Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Sandoz, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma. Chaparro has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma.

Figures

Figure 1
Figure 1
Main conclusions regarding the two main strategies to treat a patient with primary non-response to an anti-TNF agent: switching to a second anti-TNF or swapping for a drug with another mechanisms of action.
See this image and copyright information in PMC

References

    1. Gomollón F., Dignass A., Annese V., Tilg H., Van Assche G., Lindsay J.O., Peyrin-Biroulet L., Cullen G.J., Daperno M., Kucharzik T., et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J. Crohn’s Colitis. 2017;11:3–25. doi: 10.1093/ecco-jcc/jjw168. - DOI - PubMed
    1. Atreya R., Neurath M.F., Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front. Med. 2020;7:517. doi: 10.3389/fmed.2020.00517. - DOI - PMC - PubMed
    1. Eder P., Michalak M., Katulska K., Lykowska-Szuber L., Krela-Kazmierczak I., Stawczyk-Eder K., Klimczak K., Szymczak-Tomczak A., Linke K. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies. Sci. Rep. 2015;5:10223. doi: 10.1038/srep10223. - DOI - PMC - PubMed
    1. Sochal M., Krzywdzińska M., Gabryelska A., Talar-Wojnarowska R., Białasiewicz P., Małecka-Panas E. A simple index to predict the efficiency of adalimumab treatment in Crohn’s disease with a limited duration of therapy. Pol. Arch. Intern. Med. 2020;130:910–912. doi: 10.20452/pamw.15507. - DOI - PubMed
    1. Stidham R.W., Lee T.C., Higgins P.D., Deshpande A.R., Sussman D.A., Singal A.G., Elmunzer B.J., Saini S.D., Vijan S., Waljee A.K. Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment. Pharmacol. Ther. 2014;39:1349–1362. doi: 10.1111/apt.12749. - DOI - PMC - PubMed

LinkOut - more resources